Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

Jakob Lovén,^{1,7} Heather A. Hoke,^{1,2,7} Charles Y. Lin,^{1,3,5,7} Ashley Lau,^{1,2} David A. Orlando,¹ Christopher R. Vakoc,⁴ James E. Bradner,^{5,6} Tong Ihn Lee,¹ and Richard A. Young^{1,2,*}

¹Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA

²Department of Biology

³Computational and Systems Biology Program

Massachusetts Institute of Technology, Cambridge, MA 02139, USA

⁴Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA

⁵Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA

⁶Department of Medicine, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA

⁷These authors contributed equally to this work

*Correspondence: young@wi.mit.edu

http://dx.doi.org/10.1016/j.cell.2013.03.036

SUMMARY

Chromatin regulators have become attractive targets for cancer therapy, but it is unclear why inhibition of these ubiquitous regulators should have gene-specific effects in tumor cells. Here, we investigate how inhibition of the widely expressed transcriptional coactivator BRD4 leads to selective inhibition of the MYC oncogene in multiple myeloma (MM). BRD4 and Mediator were found to co-occupy thousands of enhancers associated with active genes. They also co-occupied a small set of exceptionally large super-enhancers associated with genes that feature prominently in MM biology, including the MYC oncogene. Treatment of MM tumor cells with the BET-bromodomain inhibitor JQ1 led to preferential loss of BRD4 at super-enhancers and consequent transcription elongation defects that preferentially impacted genes with super-enhancers, including MYC. Super-enhancers were found at key oncogenic drivers in many other tumor cells. These observations have implications for the discovery of cancer therapeutics directed at components of super-enhancers in diverse tumor types.

INTRODUCTION

Chromatin regulators are attractive as therapeutic targets for cancer because they are deregulated in numerous cancers (Baylin and Jones, 2011; Elsässer et al., 2011; Esteller, 2008; Feinberg and Tycko, 2004; You and Jones, 2012) and are amenable to small-molecule inhibition (Cole, 2008; Dawson and Kouzarides, 2012; Geutjes et al., 2012). Inhibition of some chromatin regulators has already proven to be efficacious for treatment of certain cancers (Issa and Kantarjian, 2009; Marks and Xu, 2009). Most chromatin regulators, however, are expressed in a broad range of healthy cells and contribute generally to gene expression, so inhibition of these important genome-associated proteins might be expected to adversely affect global gene expression in healthy cells and thus produce highly toxic effects. Nonetheless, inhibitors of some chromatin regulators, such as BRD4, have been shown to selectively inhibit transcription of key oncogenic drivers such as *c-MYC* (hereafter referred to as *MYC*) in multiple tumor types (Dawson et al., 2011; Delmore et al., 2011; Mertz et al., 2011; Zuber et al., 2011). It is important to understand how inhibition of a widely expressed, general regulator such as BRD4 can exert a selective effect on the expression of a small number of genes in specific cells.

BRD4 is a member of the bromodomain and extraterminal (BET) subfamily of human bromodomain proteins, which includes BRDT, BRD2, BRD3, and BRD4. These proteins associate with acetylated chromatin and facilitate transcriptional activation (LeRoy et al., 2008; Rahman et al., 2011). BRD4 was first identified as an interaction partner of the murine Mediator coactivator complex (Jiang et al., 1998) and was subsequently shown to associate with Mediator in a variety of human cells (Dawson et al., 2011; Wu and Chiang, 2007). BRD4 is involved in the control of transcriptional elongation by RNA polymerase II (RNA Pol II) through its recruitment of the positive transcription elongation factor P-TEFb (Jang et al., 2005; Yang et al., 2005). Almost all human cells express the BRD4 gene, based on analysis of human tissue expression data across 90 distinct tissue types (human body index - transcriptional profiling, see Extended Experimental Procedures), and BRD4 is found to be associated with a large population of active genes in CD4⁺ T cells (Zhang et al., 2012). It is not yet clear whether the BRD4 protein is generally involved in the transcription of active genes in tumor cells or if it is selectively associated with a subset of these genes.



Two recently developed bromodomain inhibitors, JQ1 and iBET, selectively bind to the amino-terminal twin bromodomains of BRD4 (Filippakopoulos et al., 2010; Nicodeme et al., 2010). These BET inhibitors cause selective repression of the potent *MYC* oncogene in a range of tumors, including multiple myeloma (MM), Burkitt's lymphoma (BL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) (Dawson et al., 2011; Delmore et al., 2011; Mertz et al., 2011; Ott et al., 2012; Zuber et al., 2011). The inhibition of *MYC* apparently occurs as a consequence of BRD4 depletion at the enhancers that drive *MYC* expressed in mouse tissues, mice are reasonably tolerant of the levels of BET bromodomain inhibition that inhibit certain tumors in mouse models (Dawson et al., 2011; Delmore et al., 2011; Filippakopoulos et al., 2010; Mertz et al., 2011; Zuber et al., 2011).

The MM cell line (MM1.S) used to study the effects of JQ1 has an IgH-MYC rearrangement, and MYC gene expression is driven by factors associated with the IgH enhancer (Dib et al., 2008; Shou et al., 2000). Enhancers function through cooperative and synergistic interactions between multiple transcription factors and coactivators (Carey et al., 1990; Giese et al., 1995; Kim and Maniatis, 1997; Thanos and Maniatis, 1995). Cooperative binding and synergistic activation confer increased sensitivity so that small changes in activator concentration can lead to dramatic changes in activator binding and transcription of associated genes (Carey, 1998). Furthermore, enhancers with large numbers of transcription factor binding sites can be more sensitive to small changes in factor concentration than those with smaller numbers of binding sites (Giniger and Ptashne, 1988; Griggs and Johnston, 1991). This concept led us to postulate that some features of the IgH enhancer might account for the selective effect of BRD4 inhibition.

We show here that BRD4 and Mediator are associated with most active enhancers and promoters in MM1.S tumor cells, but exceptionally high levels of these cofactors occur at a small set of large enhancer regions, which we call super-enhancers. Super-enhancers are associated with MYC and other key genes that feature prominently in the biology of MM, including many lineage-specific survival genes. Treatment of MM tumor cells with the BRD4 inhibitor JQ1 caused a preferential loss of BRD4, Mediator, and P-TEFb at super-enhancers and caused preferential loss of transcription at super-enhancer-associated genes, including the MYC oncogene. Tumor cell addiction to high-level expression of these oncogenes may then contribute to their vulnerability to super-enhancer disruption (Chin et al., 1999; Felsher and Bishop, 1999; Jain et al., 2002; Weinstein, 2002). We find super-enhancers in additional tumor types, where they are similarly associated with key oncogenes. Thus, key oncogene drivers of tumor cells are regulated by super-enhancers, which can confer disproportionate sensitivity to loss of the BRD4 coactivator and thus cause selective inhibition of transcription.

RESULTS

BRD4 and Mediator Co-occupy Promoters of Active Genes in Multiple Myeloma

Transcription factors bind to enhancers and recruit the Mediator coactivator, which in turn becomes associated with RNA Pol II

at the transcription start site (TSS), thus forming DNA loops between enhancers and core promoters (Kagey et al., 2010). BRD4 is known to associate with Mediator in some mammalian cells (Dawson et al., 2011; Jiang et al., 1998; Wu et al., 2003). To identify active promoter and enhancer elements and to determine how BRD4 and Mediator occupy the genome in MM1.S MM cells, we used chromatin immunoprecipitation coupled to high-throughput sequencing (chromatin immunoprecipitation [ChIP]-seq) with antibodies against the Mediator subunit MED1, BRD4, the enhancer-associated histone modification H3K27Ac, and the TSS-associated histone modification H3K4Me3 (Figure 1). ChIP-seq signals for both Mediator and the histone modification H3K27Ac have previously been shown to occur at both enhancers and TSSs (Creyghton et al., 2010; Heintzman et al., 2009; Rada-Iglesias et al., 2011), and enhancers can be distinguished from TSSs by the absence of TSS annotation and relatively low levels of H3K4Me3. We found that BRD4 co-occupied enhancers and TSSs with MED1 throughout the genome (Figures 1A and 1B) and that the levels of BRD4 and MED1 were strongly correlated (Figure S1 available online).

To confirm that BRD4 and Mediator are generally associated with active genes in MM1.S cells, we compared the ChIP-seq data for these regulators with that for RNA Pol II and the histone modification H3K4Me3. The levels of BRD4 and Mediator correlated with the levels of RNA Pol II genome wide (Figure 1C). Signals for BRD4 and Mediator were found together with those for the histone modification H3K4Me3 and RNA Pol II at ~10,000 annotated TSSs, and these were considered active TSSs (Table S1). Signals for BRD4 and the enhancer-associated histone modification H3K27Ac were found in ~8,000 Mediator-occupied regions either lacking TSSs or extending beyond the immediate vicinity of the TSS, and these were considered enhancer regions (Table S2, Data S1, and Extended Experimental Procedures).

Super-Enhancers Are Associated with Key Multiple Myeloma Genes

Further analysis of the ~8,000 enhancer regions revealed that the MED1 signal at 308 enhancers was significantly greater than at all other enhancers and promoters (Figures 2A and S2A and Table S2). These 308 super-enhancers differed from typical enhancers in both size and Mediator levels (Figure 2B). Remarkably, ~40% of all enhancer-bound Mediator and BRD4 occupied these 308 super-enhancers. Whereas the typical enhancer had a median size of 1.3 kb, the super-enhancers had a median size of 19.4 kb. These super-enhancers were thus 15-fold larger than typical enhancers and were occupied, based on ChIP-seq signal, by 18-fold more Mediator and 16-fold more BRD4. Similarly high levels of H3K27Ac were observed in these large regions (Figure 2B). Examples of gene tracks showing super-enhancers at either end of the spectrum of Mediator occupancy (Figure 2A) are shown in Figure 2C. The largest super-enhancer was found associated with the IGLL5 gene, which encodes an immunoglobulin lambda peptide expressed at high levels in these cells.

We next sought to identify the complete set of MM1.S genes that are most likely associated with super-enhancers. Enhancers tend to loop to and associate with adjacent genes in order to activate their transcription (Göndör and Ohlsson, 2009; Lelli



Figure 1. Mediator and BRD4 Co-occupy Promoters of Active Genes in Multiple Myeloma

(A) Gene tracks of MED1, BRD4, H3K27Ac, and H3K4Me3 ChIP-seq occupancy at the enhancer (left) and promoter (right) of *SMARCA4* in MM1.S MM cells. The x axis shows genomic position, and enhancer-containing regions are depicted with a white box. The y axis shows signal of ChIP-seq occupancy in units of reads per million mapped reads per base pair (rpm/bp).

(B) Metagene representation of global MED1, BRD4, H3K27Ac, and H3K4Me3 occupancy at enhancers and promoters. The x axis shows the ±2.5 kb region flanking either the center of enhancer regions (left) or the TSS of active genes (right). The y axis shows the average background subtracted ChIP-seq signal in units of rpm/bp.

et al., 2012; Ong and Corces, 2011; Spitz and Furlong, 2012). Most of these interactions occur within a distance of ~50 kb of the enhancer (Chepelev et al., 2012). Using a simple proximity rule, we assigned all transcriptionally active genes (TSSs) to super-enhancers within a 50 kb window, a method shown to identify a large proportion of true enhancer/promoter interactions in embryonic stem cells (Dixon et al., 2012). This identified 681 genes associated with super-enhancers (Table S3), and 307 of these had a super-enhancer overlapping a portion of the gene, as shown for *CCND2* in Figure 2C.

Super-enhancer-associated genes were generally expressed at higher levels than genes with typical enhancers and tended to be specifically expressed in MM1.S cells (Figure 2D). To test whether components of super-enhancers confer stronger activity compared to typical enhancer, we cloned representative super-enhancer or typical enhancer fragments of similar size into luciferase reporter constructs and transfected these into MM1.S cells. Cloned sequence fragments from super-enhancers generated 2- to 3-fold higher luciferase activity compared to typical enhancers of similar size (Figure 2E and Extended Experimental Procedures). These results are consistent with the notion that super-enhancers help to activate high levels of transcription of key genes that regulate and enforce the MM1.S cancer cell state.

The super-enhancer-associated genes included most genes that have previously been shown to have important roles in MM biology, including MYC, IRF4, PRDM1/BLIMP-1, and XBP1 (Figure 3A). MYC is a key oncogenic driver in MM (Chng et al., 2011; Dib et al., 2008; Holien et al., 2012; Shou et al., 2000), and the MM1.S MYC locus contains a chromosomal rearrangement that places MYC under the control of the IgH enhancer, which qualifies as a super-enhancer in MM1.S cells. The IRF4 gene encodes a key plasma cell transcription factor that is frequently deregulated in MM (Shaffer et al., 2008). PRDM1/BLIMP-1 encodes a transcription factor that is considered a master regulator of plasma cell development and is required for the formation of plasma cell tumors in a mouse model (Shapiro-Shelef et al., 2003; Turner et al., 1994). XBP1 encodes a basic-region leucine zipper (bZIP) transcription factor of the CREB-ATF family that governs plasma cell differentiation (Reimold et al., 2001). XBP1 is frequently overexpressed in human MM and can drive the development of MM in a mouse model (Carrasco et al., 2007; Claudio et al., 2002).

Super-enhancers were associated with many additional genes that have important roles in cancer pathogenesis more generally (Figure 3B). Cyclin D2 (*CCND2*) is deregulated in many human cancers, including MM (Bergsagel et al., 2005; Musgrove et al., 2011). The PIM1 kinase has been implicated in the biology of many different cancers (Shah et al., 2008). *MCL1* and *BCL-xL*, members of the BCL-2 family of apoptosis regulators, are frequently deregulated in cancer, promoting cell survival and

⁽C) Median MED1 and BRD4 levels in the ± 1 kb region around the TSSs of actively transcribed genes ranked by increasing RNA Pol II occupancy in MM1.S cells. Levels are in units of rpm/bp, with the left y axis showing levels of MED1 and the right y axis showing levels of BRD4. Promoters were binned (50/bin), and a smoothing function was applied to median levels. See also Figure S1.





Figure 2. Super-Enhancers Identified in Multiple Myeloma

(A) Total MED1 ChIP-seq signal in units of reads per million in enhancer regions for all enhancers in MM1.S. Enhancers are ranked by increasing MED1 ChIP-seq signal.

(B) Metagene representation of global MED1 (red line) and BRD4 (blue line) occupancy at typical enhancers and super-enhancers. The x axis shows the start and end of the enhancer (left) or super-enhancer (right) regions flanked by ± 5 kb of adjacent sequence. Enhancer and superenhancer regions on the x axis are relatively scaled. The y axis shows the average signal in units of rpm/bp.

(C) Gene tracks of MED1 (top) and BRD4 (bottom) ChIP-seq occupancy at the typical enhancer upstream of TOP1, the super-enhancer downstream of IGLL5, the typical enhancer upstream of SMARCA4, and the super-enhancer overlapping the CCND2 gene TSS. The x axis shows genomic position, and super-enhancer-containing regions are depicted with a gray box. The y axis shows signal of ChIP-seq occupancy in units of rpm/bp. (D) Left: box plots of expression values for genes with proximal typical enhancers (white) or with proximal super-enhancers (pink). The vaxis shows expression value in Log2 arbitrary units. Right: box plots of cell-type specificity values for genes with proximal typical enhancers (white) or with proximal super-enhancers (purple). The y axis shows the Z score of the Jensen-Shannon (JS) divergence statistic for genes, with higher values corresponding to a more cell-type-specific pattern of expression. Changes between expression levels are significant (two-tailed Welch's t test, p < 2 × 10⁻¹⁶), as are changes between cell-type-specificity levels (two-tailed Welch's t test, $p = 1 \times$ 10 - 14).

(E) Bar graph depicting luciferase activity of reporter constructs containing cloned fragments of typical enhancers and super-enhancers in MM1.S cells. 2 kb fragments of three super-enhancers, IGLL5, DUSP5, and SUB1, and three typical enhancers, PDHX, SERPINB8, and TOP1, ranked 1, 129, 227, 2352, 4203, and 4794, respectively, in terms of MED1 occupancy, were cloned into reporter plasmids downstream of the luciferase gene, driven by a minimal *MYC* promoter. Luciferase activity is represented as fold over empty vector. Error bars represent SD of triplicate experiments.

See also Figure S2 and Data S1.

chemoresistance (Beroukhim et al., 2010). We conclude that super-enhancers are frequently associated with genes that feature prominently in the biology of MM and other human cancers.

Inhibition of BRD4 Leads to Displacement of BRD4 Genome Wide

BRD4 interacts with chromatin-associated proteins such as transcription factors, the Mediator complex, and acetylated histones (Dawson et al., 2011; Dey et al., 2003; Jang et al., 2005; Jiang et al., 1998; Wu and Chiang, 2007; Wu et al., 2013). Pre-

vious studies have shown that treatment of MM1.S cells with JQ1 leads to reduced levels of BRD4 at the *IgH* enhancer that drives *MYC* expression (Delmore et al., 2011), but it is not clear whether such treatment causes a general reduction in the levels of BRD4 associated with the genome. We found that treatment of MM1.S cells with 500 nM JQ1 for 6 hr reduced the levels of BRD4 genome wide by ~70% (Figures 4A and 4B). This reduction in BRD4 occupancy was evident both by inspection of individual gene tracks (Figure 4C) and through global analysis of the average effects at enhancers and TSSs



Figure 3. Super-Enhancers Are Associated with Key Multiple Myeloma Genes

(A and B) Gene tracks of MED1 and BRD4 ChIP-seq occupancy at super-enhancers near genes with important roles in MM biology (A) or genes with important roles in cancer (B). Super-enhancers are depicted in gray boxes over the gene tracks. The x axis shows genomic position, and super-enhancer-containing regions are depicted with a gray box. The y axis shows signal of ChIP-seq occupancy in units of rpm/bp.

(Figure 4D). JQ1 treatment led to ${\sim}60\%$ reduction in BRD4 signal at enhancers and ${\sim}90\%$ reduction at promoters (Figure 4D). The reduction in BRD4 was more profound at super-

enhancers such as those associated with *IgH-MYC* and *CCND2* (Figure 4E), where the loss of BRD4 was nearly complete. We conclude that BET bromodomain inhibition of BRD4



Figure 4. Inhibition of BRD4 Leads to Loss of BRD4 Genome Wide (A) Tracks showing BRD4 ChIP-seq occupancy on the 35 Mb right arm of chromosome 21 after DMSO (top) or 500 nM JQ1 (bottom) treatment. The chromosome 21 ideogram is displayed above the gene tracks with the relevant region highlighted in blue. The x axis of the gene tracks shows genomic position, and the y axis shows BRD4 ChIP-seq signal in units of rpm/bp.

leads to reduced levels of BRD4 at enhancers and promoters throughout the genome in MM1.S cells.

Transcription of Super-Enhancer-Associated Genes Is Highly Sensitive to BRD4 Inhibition

Enhancers are formed through cooperative and synergistic binding of multiple transcription factors and coactivators (Carey, 1998; Carey et al., 1990; Giese et al., 1995; Kim and Maniatis, 1997; Thanos and Maniatis, 1995). As a consequence of this binding behavior, enhancers bound by many cooperatively interacting factors lose activity more rapidly than enhancers bound by fewer factors when the levels of enhancer-bound factors are reduced (Giniger and Ptashne, 1988; Griggs and Johnston, 1991). The presence of super-enhancers at *MYC* and other key genes associated with MM led us to consider the hypothesis that super-enhancers are more sensitive to reduced levels of BRD4 than typical enhancers and that genes associated with super-enhancers might then experience a greater reduction of transcription than genes with average enhancers when BRD4 is inhibited (Figure 5A).

To test this hypothesis, we first examined the effects of various concentrations of JQ1 on BRD4 occupancy genome wide (Figure 5B). JQ1 had little effect on MM1.S cell viability when treated for 6 hr at these various concentrations, whereas at later time points, JQ1 had a significant antiproliferative effect (Figure 5C). As expected. MYC protein levels were significantly depleted by exposure of MM1.S cells to 50 nM or greater doses of JQ1 for 6 hr (Figure 6D) (Delmore et al., 2011). In contrast, JQ1 did not affect total BRD4 protein levels within the cells and did not significantly reduce ChIP efficiency (Figure 5E). When BRD4 occupancy was examined genome wide in cells exposed to increasing concentrations of JQ1, it was evident that super-enhancers showed a greater loss of BRD4 occupancy than typical enhancer regions (Figure 5F). For example, the IgH superenhancer showed significantly greater reduction in BRD4 occupancy in cells treated with 5 nM or 50 nM JQ1 than typical enhancer regions such as that upstream of SMARCA4 (Figure 5G). Ultimately, virtually all BRD4 occupancy was lost at the IgH super-enhancer (97% reduction versus DMSO control)

(E) Gene tracks of BRD4 binding at super-enhancers after DMSO (top) or 500 nM JQ1 (bottom) treatment. The x axis shows genomic position, and super-enhancer-containing regions are depicted with a gray box. The y axis shows signal of ChIP-seq occupancy in units of rpm/bp.

⁽B) Box plot showing the distributions of BRD4 ChIP-seq signal at BRD4-enriched regions after DMSO (left) or 500 nM JQ1 (right) treatment. BRD4-enriched regions were defined in MM1.S cells treated with DMSO. The y axis shows BRD4 ChIP-seq signal in units of rpm/bp. The loss of BRD4 occupancy at BRD4-enriched regions after JQ1 is highly significant (p value < 1×10^{-16} , Welch's t test).

⁽C) Gene tracks of BRD4 ChIP-seq occupancy at the enhancer (left) and promoter (right) of *SMARCA4* in MM1.S cells after DMSO (top) or 500 nM JQ1 (bottom) treatment for 6 hr. The x axis shows genomic position, and enhancercontaining regions are depicted with a white box. The y axis shows signal of ChIP-seq occupancy in units of rpm/bp.

⁽D) Metagene representation of global BRD4 occupancy at enhancers and promoters after DMSO (solid line) or 500 nM JQ1 (dotted line) treatment. The x axis shows the ± 2.5 kb region flanking either the center of enhancer regions (left) or the TSS of active genes. The y axis shows the average background subtracted ChIP-seq signal in units of rpm/bp.





Figure 5. BRD4 Occupancy at Super-Enhancers Is Highly Sensitive to Bromodomain Inhibition

(A) Schematic example of how cooperative interactions of enhancer-associated factors at super-enhancers lead to both higher transcriptional output and increased sensitivity to factor concentration.

(B) Measuring the effects of various concentrations of JQ1 genome wide on BRD4 occupancy. Schematic depicting the experimental procedure.

(C) Short-term JQ1 treatment (6 hr) has little effect on MM1.S cell viability. JQ1 sensitivity of MM1.S cells by measurement of ATP levels (CellTiterGlo) after 6, 24, 48, and 72 hr of treatment with JQ1 (5, 50, 500, or 5,000 nM) or vehicle (DMSO, 0.05%). Error bars represent the SD of triplicate experiments.

(D) Western blot of relative MYC levels after 6 hr of JQ1 or DMSO treatment.

(E) Western blot of relative BRD4 levels after 6 hr of JQ1 or DMSO treatment. ChIP-western blot of the relative levels of immunoprecipitated BRD4 after 6 hr of JQ1 or DMSO treatment.

(F) Line graph showing the percentage of BRD4 occupancy remaining after 6 hr treatment at various JQ1 concentrations for typical enhancers (gray line) or superenhancers (red line). The y axis shows the fraction of BRD4 occupancy remaining versus DMSO. The x axis shows different JQ1 concentrations (DMSO [none], 5 nM, 50 nM, and 500 nM). Error bars represent 95% confidence intervals of the mean (95% CI). after treatment with 500 nM JQ1, whereas loss of BRD4 occupancy at the typical enhancer for *SMARCA4* was less pronounced (71% reduction versus DMSO control) (Figure 5G).

We next investigated whether genes associated with superenhancers might experience a greater reduction of transcription than genes with average enhancers when BRD4 is inhibited. As expected, treatment of MM1.S cells with 500 nM JQ1 led to progressive reduction in global messenger RNA (mRNA) levels over time (Figures 6A and S3A). Similarly, treatment with increasing concentrations of JQ1 caused progressive reductions in global mRNA levels (Figures 6A and S3B). There was a selective depletion of mRNAs from super-enhancer-associated genes that occurred in both temporal (Figure 6B) and concentration-dependent manners (Figure 6C). Notably, MYC and IRF4 mRNA levels were more rapidly depleted than other mRNAs that are expressed at similar levels (Figure 6D). The levels of transcripts from super-enhancer-associated genes were somewhat more affected than those from genes that have multiple typical enhancers bound by BRD4 (Figures S3C and S3D). Thus, BET bromodomain inhibition preferentially impacts transcription of super-enhancer-driven genes.

To further test the model that super-enhancers are responsible for the special sensitivity to BRD4 inhibition, we transfected MM1.S cells with luciferase reporter constructs containing super-enhancer and typical enhancer fragments and examined the effects of various JQ1 concentrations on luciferase activity. Upon treatment with JQ1, MM1.S cells transfected with a super-enhancer reporter experienced a greater reduction in luciferase activity than those transfected with a typical enhancer reporter (Figure 6E). Interestingly, the dose-response curve observed for luciferase activity of the super-enhancer construct is consistent with that expected for enhancers that are bound cooperatively by multiple factors (Figure 5A) (Giniger and Ptashne, 1988; Griggs and Johnston, 1991). These results are also consistent with the model that super-enhancers are responsible for the special sensitivity of gene transcription to BRD4 inhibition.

BRD4 Inhibition and Transcription Elongation

At active genes, enhancers and core promoters are brought into close proximity, so factors associated with enhancers can act on the transcription apparatus in the vicinity of TSSs and thereby influence initiation or elongation. BRD4 is known to interact with Mediator and P-TEFb and to be involved in the control of transcriptional elongation by RNA Pol II (Conaway and Conaway, 2011; Dawson et al., 2011; Jang et al., 2005; Krueger et al., 2010; Rahman et al., 2011; Yang et al., 2005). This suggests that the preferential loss of BRD4 from super-enhancers might affect the levels of Mediator and P-TEFb at these sites and, furthermore, that the reduced levels of mRNAs from super-enhancer-associated genes might be due to an effect on transcription elongation.

To test these predictions, we carried out ChIP-seq for the Mediator component MED1 and the catalytic subunit of the P-TEFb complex CDK9 in MM1.S cells treated with DMSO or 500 nM JQ1 for 6 hr. In control cells, MED1 and CDK9 were found at enhancers and promoters of active genes throughout the MM genome, as expected (Figures 1A, 1B, and S3E). In cells treated with JQ1, reduced levels of MED1 and CDK9 were observed primarily at enhancers, with the greatest loss at super-enhancers (Figure 6F). As many super-enhancers span contiguous regions that encompass or overlap the TSS, we analyzed MED1 and CDK9 loss in either TSS proximal or TSS distal regions of super-enhancers and again observed loss of MED1 and CDK9 predominantly at TSS distal regions (Figure S3F). We conclude that inhibition of BRD4 genomic binding leads to a marked reduction in the levels of Mediator and P-TEFb at genomic regions distal to TSSs, with the greatest reduction occurring at super-enhancers.

To determine whether reduced levels of BRD4 lead to changes in transcription elongation, we quantified changes in transcription elongation by performing ChIP-seq of RNA Pol II before and after treatment of MM1.S cells with 500 nM JQ1. We then calculated the fold loss of RNA Pol II occupancy in the gene body regions for all transcriptionally active genes and found that more than half of these genes show a decrease in elongating RNA Pol II density after JQ1 treatment (Figure 6G). Importantly, genes associated with super-enhancers showed a greater decrease of RNA Pol II in their elongating gene body regions compared to genes associated with typical enhancers (Figures 6H and S3G). Inspection of individual gene tracks revealed pronounced elongation defects at super-enhancer-associated genes such as MYC and IRF4, with the greatest effects observed with MYC (Figures 6I and 6J). Thus, the selective effects of JQ1 on the transcription of MYC and other super-enhancer-associated genes can be explained, at least in part, by the sensitivity of super-enhancers to reduced levels of BRD4, which leads to a pronounced effect on pause release and transcription elongation.

Super-Enhancers Are Associated with Disease-Critical Genes in Other Cancers

To map enhancers and to determine whether super-enhancers occur in additional tumor types, we investigated the genome-wide occupancy of Mediator (MED1), BRD4, and the enhancer-associated histone modification H3K27Ac using ChIP-seq in glioblastoma multiforme (GBM) and small-cell lung cancer (SCLC) (Figure 7). Mediator (MED1) occupancy was used to identify enhancer elements because enhancerbound transcription factors bind directly to Mediator (Borggrefe and Yue, 2011; Conaway and Conaway, 2011; Kornberg, 2005; Malik and Roeder, 2010; Taatjes, 2010) and because it has proven to produce high-quality evidence for enhancers in mammalian cells (Kagey et al., 2010). Global occupancy of BRD4 and H3K27Ac was used as corroborative evidence to identify enhancer elements (Figure S4 and Table S4). Analysis of the regions occupied by Mediator revealed that, as in

⁽G) Gene tracks of BRD4 ChIP-seq occupancy after various concentrations of JQ1 treatment at the *IgH-MYC*-associated super-enhancer (left) and the *SMARCA4*-associated typical enhancer (right). The x axis shows genomic position, and gray boxes depict super-enhancer regions. The y axis shows signal of ChIP-seq occupancy in units of rpm/bp. The percent of BRD4 remaining after each concentration of JQ1 treatment is annotated to the right of the gene tracks.





Figure 6. JQ1 Causes Disproportionate Loss of Transcription at Super-Enhancer Genes

(A) Box plots showing the Log₂ change in gene expression for all actively transcribed genes in JQ1-treated versus control cells for a time course of cells treated with 500 nM JQ1 (left) or for a concentration course of cells treated for 6 hr with varying amounts of JQ1 (right). The y axis shows the Log₂ change in gene expression versus untreated control cells (left graph) or control cells treated with DMSO for 6 hr (right graph).

MM1.S cells, large genomic domains were occupied by this coactivator in both GBM and SCLC (Figures 7A, 7B, 7D, and 7E). The median super-enhancer was 30 kb in GBM cells and 11 kb in SCLC cells (Figures 7B and 7E). As in MM1.S cells, these GBM and SCLC super-enhancers were an order or magnitude larger and showed a commensurate increase in MED1, BRD4, and H3K27Ac levels when compared to normal enhancers (Figures 7B and 7E).

The super-enhancers in GBM and SCLC were found to be associated with many well-known tumor-associated genes (Figures 7C and 7F and Table S5). In GBM, super-enhancers were associated with genes encoding three transcription factors (RUNX1, FOSL2, and BHLHE40) critical for mesenchymal transformation of brain tumors (Carro et al., 2010); the super-enhancers associated with BHLHE40 are shown in Figure 7C. BCL3, which associates with NF- κ B and is deregulated in many blood and solid tumor types, is associated with a superenhancer in GBM (Figure 7C) (Maldonado and Melendez-Zajgla, 2011). In SCLC, a super-enhancer is associated with the INSM1 gene, which encodes a transcription factor involved in neuronal development that is highly expressed in neuroendocrine tissue and tumors such as SCLC (Figure 7F) (Pedersen et al., 2003). A super-enhancer is also associated with the ID2 gene, which is highly expressed in SCLCs and encodes a protein that interacts with the well-known retinoblastoma tumor suppressor (Figure 7F) (Pedersen et al., 2003; Perk et al., 2005). These results indicate that super-enhancers are likely to associate with critical tumor oncogenes in diverse tumor types.

DISCUSSION

Chromatin regulators have become attractive targets for cancer therapy, but many of these regulators are expressed in a broad range of healthy cells and contribute generally to gene expression. Thus, it is unclear how inhibition of a global chromatin regulator such as BRD4 might produce selective effects, such as at the *MYC* oncogene (Delmore et al., 2011). We have found that key regulators of tumor cell state in MM1.S cells are associated with large enhancer domains, characterized by disproportionately high levels of BRD4 and Mediator. These super-enhancers are more sensitive to perturbation than typical enhancers, and the expression of the genes associated with super-enhancers is preferentially affected. Thus, the preferential loss of BRD4 at super-enhancers associated with the *MYC* oncogene and other key tumor-associated genes can explain the gene-selective effects of JQ1 treatment in these cells.

BRD4 is an excellent example of a chromatin regulator that is expressed in a broad range of healthy cells and contributes generally to gene expression. Most cell types for which RNA-seq data are available express the *BRD4* gene. ChIP-seq data revealed that BRD4 generally occupies the enhancer and promoter elements of active genes with the Mediator coactivator in MM1.S cells (Figure 1). These results eliminate the model that BRD4 is exclusively associated with a small set of genes that are thereby rendered inactive by the BRD4 inhibitor JQ1 and instead suggest that the gene-specific effects of the small molecule have other causes.

We have found that ~3% of the enhancers in MM1.S cells are exceptionally large and are occupied by remarkably high amounts of BRD4 and Mediator. These super-enhancers are generally an order of magnitude larger and contain an order of magnitude more BRD4, Mediator, and histone marks associated with enhancers (H3K27Ac) than typical enhancers. Our results suggest that super-enhancers are collections of closely spaced enhancers that can collectively facilitate high levels of transcription from adjacent genes. Importantly, the super-enhancers are associated with the *MYC* oncogene and additional genes such as *IGLL5*, *IRF4*, *PRDM1/BLIMP-1*, and *XBP1* that feature prominently in MM biology.

Cooperative and synergistic binding of multiple transcription factors and coactivators occurs at enhancers. Enhancers bound by many cooperatively interacting factors can lose activity more rapidly than enhancers bound by fewer factors when the levels of enhancer-bound factors are reduced (Giniger and Ptashne, 1988; Griggs and Johnston, 1991). The presence of super-enhancers at *MYC* and other key genes associated with MM led us to test the hypothesis that super-enhancers are more sensitive to reduced levels of BRD4 than average enhancers. We

(I and J) Gene tracks of RNA Pol II ChIP-seq occupancy after DMSO (black) or 500 nM JQ1 treatment (red) at the super-enhancer proximal *MYC* gene (I) and *IRF4* gene (J). The y axis shows signal of ChIP-seq occupancy in units of rpm/bp. See also Figure S3.

⁽B and C) Line graph showing the Log2 change in gene expression versus control cells after JQ1 treatment in a time- (B) or dose (C)-dependent manner for genes associated with typical enhancers (gray line) or genes associated with super-enhancers (red line). The y axis shows the Log2 change in gene expression of JQ1 treated versus untreated control cells. The x axis shows time of 500 nM JQ1 treatment (B) or JQ1 treatment concentration at 6 hr (C). Error bars represent 95% confidence intervals of the mean (95% CI).

⁽D) Graph showing the Log₂ change in gene expression after JQ1 treatment over time for genes ranked in the top 10% of expression in MM1.S cells. Each line represents a single gene, with the *MYC* and *IRF4* genes drawn in red. The y axis shows the Log₂ change in gene expression of JQ1-treated versus untreated control cells. The x axis shows time of 500 nM JQ1 treatment.

⁽E) Line graph showing luciferase activity after JQ1 treatment at various concentrations for luciferase reporter constructs containing either a fragment from the *IGLL5* super-enhancer (red line) or the *PDHX* typical enhancer (gray line). The y axis represents relative luciferase activity in arbitrary units. The x axis shows JQ1 concentrations. Error bars are SEM.

⁽F) Bar graphs showing the percentage loss of either MED1 (top, red) or CDK9 (bottom, green) at promoters, typical enhancers, and super-enhancers. Error bars represent 95% Cl.

⁽G) Graph of loss of RNA Pol II density in the elongating gene body region for all transcriptionally active genes in MM1.S cells after 6 hr of 500 nM JQ1 treatment. Genes are ordered by decrease in elongating RNA Pol II in units of Log₂ fold loss. Genes with a greater than 0.5 Log₂ fold change in elongating RNA Pol II are shaded in green (loss) or red (gain). The amount of RNA Pol II loss is indicated for select genes.

⁽H) Bar graph showing the Log₂ fold change in RNA Pol II density in elongating gene body regions after 6 hr of 500 nM JQ1 treatment for genes with typical enhancers (left, gray) or genes with super-enhancers (red, right). Error bars represent 95% confidence intervals of the mean (95% Cl).





found that treatment of these tumor cells with the BET-bromodomain inhibitor JQ1 leads to preferential loss of BRD4 at super-enhancers. In addition, this decrease in BRD4 occupancy is accompanied by a corresponding loss of MED1 and CDK9 at super-enhancers. Consequent transcription elongation defects and mRNA decreases preferentially impact super-enhancerassociated genes, with an especially profound effect at the *MYC* oncogene.

Super-enhancers are not restricted to MM cells. We have identified super-enhancers in two additional tumor types, small-cell lung cancer and glioblastoma multiforme. Super-enhancers identified in these cell types have characteristics similar to those found in MM1.S; they span large genomic regions and contain exceptional amounts of Mediator and BRD4. These superenhancers are also associated with important tumor genes in both cell types. In GBM cells, *BHLHE40* and *BCL3* are known to be important in tumor biology and are each associated with super-enhancers in this cell type. In H2171 SCLC cells, superenhancers are associated with *INSM1* and *ID2*, which are frequently overexpressed in SCLC. In fact, super-enhancers are not restricted to tumor cells and have been identified in several additional cell types in which they similarly associate with key cell identity genes (Whyte et al., 2013 [this issue of *CelI*]).

Our results demonstrate that super-enhancers occupied by BRD4 regulate critical oncogenic drivers in MM and show that BRD4 inhibition leads to preferential disruption of these superenhancers. This insight into the mechanism by which BRD4 inhibition causes selective loss of oncogene expression in this highly malignant blood cancer may have implications for future drug development in oncology. Tumor cells frequently become addicted to oncogenes, thus becoming unusually reliant on high-level expression of these genes (Cheung et al., 2011; Chin et al., 1999; Felsher and Bishop, 1999; Garraway and Sellers, 2006; Garraway et al., 2005; Jain et al., 2002; Weinstein, 2002). Thus, preferential disruption of super-enhancer function may be a general approach to selectively inhibiting the oncogenic drivers of many tumor cells.

EXPERIMENTAL PROCEDURES

Cell Culture

MM1.S MM cells (CRL-2974 ATCC) and U-87 MG glioblastoma cells (HTB-14 ATCC) were purchased from ATCC. H2171 small-cell lung carcinoma cells (CRL-5929 ATCC) were kindly provided by John Minna, UT Southwestern. MM1.S and H2171 cells were propagated in RPMI-1640 supplemented with 10% fetal bovine serum and 1% GlutaMAX (Invitrogen, 35050-061). U-87 MG cells were cultured in Eagle's minimum essential medium (EMEM) modified to contain Earle's Balanced Salt Solution, nonessential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1,500 mg/l sodium bicarbonate. Cells were grown at 37°C and 5% CO₂.

For JQ1 treatment experiments, cells were resuspended in fresh media containing JQ1 (5 nM, 50 nM, 500 nM, and 5,000 nM) or vehicle (DMSO, 0.05%) and treated for a duration of 6 hr, unless otherwise indicated.

ChIP-Seq

ChIP was carried out as described in Lin et al. (2012). Additional details are provided in Extended Experimental Procedures. Antibodies used are as follows: total RNA Pol II (Rpb1 N terminus), Santa Cruz sc-899 lot K0111; MED1, Bethyl Labs A300-793A lot A300-793A-2; BRD4, Bethyl Labs A301-985A lot A301-985A-1; CDK9, Santa Cruz Biotechnology sc-484, lot D1612. ChIP-seq data sets of H3K4Me3 and H3K27Ac in MM1.S and MED1 and H3K27Ac in U-87 MG and H2171 were previously published (Lin et al., 2012).

Luciferase Reporter Assays

A minimal Myc promoter was amplified from human genomic DNA and cloned into the SacI and HindIII sites of the pGL3 basic vector (Promega). Enhancer fragments were likewise amplified from human genomic DNA and cloned into the BamHI and SalI sites of the pGL3-pMyc vector. All cloning primers are listed in Table S6. Constructs were transfected into MM1.S cells using Lipofectamine 2000 (Invitrogen). The pRL-SV40 plasmid (Promega) was co-transfected as a normalization control. Cells were incubated for 24 hr, and luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega). For the JQ1 concentrations of JQ1 24 hr after transfection and were incubated for an additional 6 hr before harvesting. Luminescence measurements were made using the Dual-Luciferase Reporter Assay System (Promega) on a Wallac EnVision (Perkin Elmer) plate reader.

Cell Viability Assays

Cell viability was measured using the CellTiterGlo assay kit (Promega, G7571). MM1.S cells were resuspended in fresh media containing JQ1 (5 nM, 50 nM, 500 nM, and 1,000 nM) or vehicle (DMSO, 0.05%) and then plated in 96-well plates at 10,000 cells/well in a volume of 100 μ l. Viability was measured after 6, 24, 48, and 72 hr incubations by addition of CellTiter Glo reagent and luminescence measurement on a Tecan Safire² plate reader.

Western Blotting

Western blots were carried out using standard protocols. Antibodies used are as follows: c-Myc (Epitomics, category: 1472-1), BRD4 (Epitomics, category: 5716-1) or β -actin (Sigma, clone AC-15, A5441).

Data Analysis

All ChIP-seq data sets were aligned using Bowtie (version 0.12.9) (Langmead et al., 2009) to build version NCBI36/HG18 of the human genome. Individual data set GEO accession IDs and background data sets used can be found in Table S7.

ChIP-seq read densities in genomic regions were calculated as in Lin et al. (2012). We used the MACS version 1.4.2 (model-based analysis of ChIP-seq) (Zhang et al., 2008) peak finding algorithm to identify regions of ChIP-seq enrichment over background. A p value threshold of enrichment of 1 × 10^{-9} was used for all data sets.

Active enhancers were defined as regions of ChIP-seq enrichment for the mediator complex component MED1 outside of promoters (e.g., a region not contained within ±2.5 kb region flanking the promoter). In order to accurately capture dense clusters of enhancers, we allowed MED1 regions within 12.5 kb of one another to be stitched together. To identify super-enhancers, we first

Figure 7. Super-Enhancers Are Associated with Key Genes in Other Cancers

(A and D) Total MED1 ChIP-seq signal in units of reads per million in enhancer regions for all enhancers in (A) the GBM cell line U-87 MG or (D) the SCLC cell line H2171. Enhancers are ranked by increasing MED1 ChIP-seq signal.

(B and E) Metagene representation of global MED1 and BRD4 occupancy at (B) typical GMB enhancers and super-enhancers or (E) typical SCLC enhancers and super-enhancers. The x axis shows the start and end of the enhancer (left) or super-enhancer (right) regions flanked by ±5 kb of adjacent sequence. Enhancer and super-enhancer regions on the x axis are relatively scaled. The y axis shows the average signal in units of rpm/bp.

(C and F) Gene tracks of MED1 and BRD4 ChIP-seq occupancy at (C) super-enhancers near *BHLHE40* and *BCL3*, genes with important roles in GBM, or at (F) super-enhancers near *INSM1* and *ID2*, genes with important roles in SCLC. Super-enhancers are depicted in gray boxes over the gene tracks. See also Figure S4.

ranked all enhancers by increasing total background subtracted ChIP-seqoccupancy of MED1 (x axis) and plotted the total background subtracted ChIP-seq occupancy of MED1 in units of total rpm (y axis). This representation revealed a clear inflection point in the distribution of MED1 at enhancers. We geometrically defined the inflection point and used it to establish the cutoff for super-enhancers (see Extended Experimental Procedures).

ACCESSION NUMBERS

The GEO accession number for the ChIP-seq and gene expression data reported in this paper is GSE44931 (http://www.ncbi.nlm.nih.gov/geo/).

SUPPLEMENTAL INFORMATION

Supplemental Information includes Extended Experimental Procedures, four figures, one data file, and seven tables and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2013.03.036.

ACKNOWLEDGMENTS

We thank Zi Peng Fan for bioinformatics support; Michael R. McKeown for help with cell viability assays; Jun Qi for providing JQ1; Tom Volkert, Jennifer Love, Sumeet Gupta, and Jeong-Ah Kwon at the Whitehead Genome Technologies Core for Solexa sequencing; and members of the Young, Bradner, and Vakoc labs for helpful discussion. This work was supported by a Swedish Research Council Postdoctoral Fellowship VR-B0086301 (J.L.), the Damon-Runyon Cancer Research Foundation (J.E.B.), a Burroughs-Welcome CAMS award and NCI Cancer Center Support Grant Development Fund CA45508 (C.R.V.), and National Institutes of Health grants HG002668 (R.A.Y.) and CA146445 (R.A.Y., T.I.L.). R.A.Y. and J.E.B. are founders, J.L. and D.A.O. have become employees, and C.R.V. is a scientific advisor of Syros Pharmaceuticals.

Received: November 16, 2012 Revised: February 25, 2013 Accepted: March 25, 2013 Published: April 11, 2013

REFERENCES

Baylin, S.B., and Jones, P.A. (2011). A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer *11*, 726–734.

Bergsagel, P.L., Kuehl, W.M., Zhan, F., Sawyer, J., Barlogie, B., and Shaughnessy, J., Jr. (2005). Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood *106*, 296–303.

Beroukhim, R., Mermel, C.H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J.S., Dobson, J., Urashima, M., et al. (2010). The landscape of somatic copy-number alteration across human cancers. Nature *463*, 899–905.

Borggrefe, T., and Yue, X. (2011). Interactions between subunits of the Mediator complex with gene-specific transcription factors. Semin. Cell Dev. Biol. *22*, 759–768.

Carey, M. (1998). The enhanceosome and transcriptional synergy. Cell *92*, 5–8. Carey, M., Leatherwood, J., and Ptashne, M. (1990). A potent GAL4 derivative activates transcription at a distance in vitro. Science *247*, 710–712.

Carrasco, D.R., Sukhdeo, K., Protopopova, M., Sinha, R., Enos, M., Carrasco, D.E., Zheng, M., Mani, M., Henderson, J., Pinkus, G.S., et al. (2007). The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell *11*, 349–360.

Carro, M.S., Lim, W.K., Alvarez, M.J., Bollo, R.J., Zhao, X., Snyder, E.Y., Sulman, E.P., Anne, S.L., Doetsch, F., Colman, H., et al. (2010). The transcriptional network for mesenchymal transformation of brain tumours. Nature *463*, 318–325. Chepelev, I., Wei, G., Wangsa, D., Tang, Q., and Zhao, K. (2012). Characterization of genome-wide enhancer-promoter interactions reveals co-expression of interacting genes and modes of higher order chromatin organization. Cell Res. *22*, 490–503.

Cheung, H.W., Cowley, G.S., Weir, B.A., Boehm, J.S., Rusin, S., Scott, J.A., East, A., Ali, L.D., Lizotte, P.H., Wong, T.C., et al. (2011). Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl. Acad. Sci. USA *108*, 12372– 12377.

Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999). Essential role for oncogenic Ras in tumour maintenance. Nature *400*, 468–472.

Chng, W.J., Huang, G.F., Chung, T.H., Ng, S.B., Gonzalez-Paz, N., Troska-Price, T., Mulligan, G., Chesi, M., Bergsagel, P.L., and Fonseca, R. (2011). Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 25, 1026–1035.

Claudio, J.O., Masih-Khan, E., Tang, H., Gonçalves, J., Voralia, M., Li, Z.H., Nadeem, V., Cukerman, E., Francisco-Pabalan, O., Liew, C.C., et al. (2002). A molecular compendium of genes expressed in multiple myeloma. Blood *100*, 2175–2186.

Cole, P.A. (2008). Chemical probes for histone-modifying enzymes. Nat. Chem. Biol. 4, 590–597.

Conaway, R.C., and Conaway, J.W. (2011). Function and regulation of the Mediator complex. Curr. Opin. Genet. Dev. 21, 225–230.

Creyghton, M.P., Cheng, A.W., Welstead, G.G., Kooistra, T., Carey, B.W., Steine, E.J., Hanna, J., Lodato, M.A., Frampton, G.M., Sharp, P.A., et al. (2010). Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA *107*, 21931–21936.

Dawson, M.A., and Kouzarides, T. (2012). Cancer epigenetics: from mechanism to therapy. Cell *150*, 12–27.

Dawson, M.A., Prinjha, R.K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.I., Robson, S.C., Chung, C.W., Hopf, C., Savitski, M.M., et al. (2011). Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529–533.

Delmore, J.E., Issa, G.C., Lemieux, M.E., Rahl, P.B., Shi, J., Jacobs, H.M., Kastritis, E., Gilpatrick, T., Paranal, R.M., Qi, J., et al. (2011). BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell *146*, 904–917.

Dey, A., Chitsaz, F., Abbasi, A., Misteli, T., and Ozato, K. (2003). The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. USA *100*, 8758–8763.

Dib, A., Gabrea, A., Glebov, O.K., Bergsagel, P.L., and Kuehl, W.M. (2008). Characterization of MYC translocations in multiple myeloma cell lines. J. Natl. Cancer Inst. Monogr. *39*, 25–31.

Dixon, J.R., Selvaraj, S., Yue, F., Kim, A., Li, Y., Shen, Y., Hu, M., Liu, J.S., and Ren, B. (2012). Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature *485*, 376–380.

Elsässer, S.J., Allis, C.D., and Lewis, P.W. (2011). Cancer. New epigenetic drivers of cancers. Science 331, 1145–1146.

Esteller, M. (2008). Epigenetics in cancer. N. Engl. J. Med. 358, 1148–1159.

Feinberg, A.P., and Tycko, B. (2004). The history of cancer epigenetics. Nat. Rev. Cancer *4*, 143–153.

Felsher, D.W., and Bishop, J.M. (1999). Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell *4*, 199–207.

Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W.B., Fedorov, O., Morse, E.M., Keates, T., Hickman, T.T., Felletar, I., et al. (2010). Selective inhibition of BET bromodomains. Nature *468*, 1067–1073.

Garraway, L.A., and Sellers, W.R. (2006). Lineage dependency and lineagesurvival oncogenes in human cancer. Nat. Rev. Cancer 6, 593–602.

Garraway, L.A., Widlund, H.R., Rubin, M.A., Getz, G., Berger, A.J., Ramaswamy, S., Beroukhim, R., Milner, D.A., Granter, S.R., Du, J., et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122.

Geutjes, E.J., Bajpe, P.K., and Bernards, R. (2012). Targeting the epigenome for treatment of cancer. Oncogene 31, 3827–3844.

Giese, K., Kingsley, C., Kirshner, J.R., and Grosschedl, R. (1995). Assembly and function of a TCR alpha enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions. Genes Dev. 9, 995–1008.

Giniger, E., and Ptashne, M. (1988). Cooperative DNA binding of the yeast transcriptional activator GAL4. Proc. Natl. Acad. Sci. USA *85*, 382–386.

Göndör, A., and Ohlsson, R. (2009). Chromosome crosstalk in three dimensions. Nature 461, 212–217.

Griggs, D.W., and Johnston, M. (1991). Regulated expression of the GAL4 activator gene in yeast provides a sensitive genetic switch for glucose repression. Proc. Natl. Acad. Sci. USA *88*, 8597–8601.

Heintzman, N.D., Hon, G.C., Hawkins, R.D., Kheradpour, P., Stark, A., Harp, L.F., Ye, Z., Lee, L.K., Stuart, R.K., Ching, C.W., et al. (2009). Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature *459*, 108–112.

Holien, T., Våtsveen, T.K., Hella, H., Waage, A., and Sundan, A. (2012). Addiction to c-MYC in multiple myeloma. Blood *120*, 2450–2453.

Issa, J.P., and Kantarjian, H.M. (2009). Targeting DNA methylation. Clin. Cancer Res. *15*, 3938–3946.

Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C.D., Bishop, J.M., and Felsher, D.W. (2002). Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science *297*, 102–104.

Jang, M.K., Mochizuki, K., Zhou, M., Jeong, H.S., Brady, J.N., and Ozato, K. (2005). The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell *19*, 523–534.

Jiang, Y.W., Veschambre, P., Erdjument-Bromage, H., Tempst, P., Conaway, J.W., Conaway, R.C., and Kornberg, R.D. (1998). Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways. Proc. Natl. Acad. Sci. USA *95*, 8538–8543.

Kagey, M.H., Newman, J.J., Bilodeau, S., Zhan, Y., Orlando, D.A., van Berkum, N.L., Ebmeier, C.C., Goossens, J., Rahl, P.B., Levine, S.S., et al. (2010). Mediator and cohesin connect gene expression and chromatin architecture. Nature *467*, 430–435.

Kim, T.K., and Maniatis, T. (1997). The mechanism of transcriptional synergy of an in vitro assembled interferon-beta enhanceosome. Mol. Cell 1, 119–129.

Kornberg, R.D. (2005). Mediator and the mechanism of transcriptional activation. Trends Biochem. Sci. 30, 235–239.

Krueger, B.J., Varzavand, K., Cooper, J.J., and Price, D.H. (2010). The mechanism of release of P-TEFb and HEXIM1 from the 7SK snRNP by viral and cellular activators includes a conformational change in 7SK. PLoS ONE *5*, e12335.

Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. *10*, R25.

Lelli, K.M., Slattery, M., and Mann, R.S. (2012). Disentangling the many layers of eukaryotic transcriptional regulation. Annu. Rev. Genet. *46*, 43–68.

LeRoy, G., Rickards, B., and Flint, S.J. (2008). The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol. Cell *30*, 51–60.

Lin, C.Y., Lovén, J., Rahl, P.B., Paranal, R.M., Burge, C.B., Bradner, J.E., Lee, T.I., and Young, R.A. (2012). Transcriptional amplification in tumor cells with elevated c-Myc. Cell *151*, 56–67.

Maldonado, V., and Melendez-Zajgla, J. (2011). Role of Bcl-3 in solid tumors. Mol. Cancer 10, 152.

Malik, S., and Roeder, R.G. (2010). The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation. Nat. Rev. Genet. *11*, 761–772. Marks, P.A., and Xu, W.S. (2009). Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell. Biochem. *107*, 600–608.

Mertz, J.A., Conery, A.R., Bryant, B.M., Sandy, P., Balasubramanian, S., Mele, D.A., Bergeron, L., and Sims, R.J., 3rd. (2011). Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. USA *108*, 16669–16674.

Musgrove, E.A., Caldon, C.E., Barraclough, J., Stone, A., and Sutherland, R.L. (2011). Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer *11*, 558–572.

Nicodeme, E., Jeffrey, K.L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010). Suppression of inflammation by a synthetic histone mimic. Nature *468*, 1119–1123.

Ong, C.T., and Corces, V.G. (2011). Enhancer function: new insights into the regulation of tissue-specific gene expression. Nat. Rev. Genet. 12, 283–293.

Ott, C.J., Kopp, N., Bird, L., Paranal, R.M., Qi, J., Bowman, T., Rodig, S.J., Kung, A.L., Bradner, J.E., and Weinstock, D.M. (2012). BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood *120*, 2843–2852.

Pedersen, N., Mortensen, S., Sørensen, S.B., Pedersen, M.W., Rieneck, K., Bovin, L.F., and Poulsen, H.S. (2003). Transcriptional gene expression profiling of small cell lung cancer cells. Cancer Res. 63, 1943–1953.

Perk, J., lavarone, A., and Benezra, R. (2005). Id family of helix-loop-helix proteins in cancer. Nat. Rev. Cancer 5, 603–614.

Rada-Iglesias, A., Bajpai, R., Swigut, T., Brugmann, S.A., Flynn, R.A., and Wysocka, J. (2011). A unique chromatin signature uncovers early developmental enhancers in humans. Nature 470, 279–283.

Rahman, S., Sowa, M.E., Ottinger, M., Smith, J.A., Shi, Y., Harper, J.W., and Howley, P.M. (2011). The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol. Cell. Biol. *31*, 2641–2652.

Reimold, A.M., Iwakoshi, N.N., Manis, J., Vallabhajosyula, P., Szomolanyi-Tsuda, E., Gravallese, E.M., Friend, D., Grusby, M.J., Alt, F., and Glimcher, L.H. (2001). Plasma cell differentiation requires the transcription factor XBP-1. Nature *412*, 300–307.

Shaffer, A.L., Emre, N.C., Lamy, L., Ngo, V.N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. (2008). IRF4 addiction in multiple myeloma. Nature 454, 226–231.

Shah, N., Pang, B., Yeoh, K.G., Thorn, S., Chen, C.S., Lilly, M.B., and Salto-Tellez, M. (2008). Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur. J. Cancer *44*, 2144–2151.

Shapiro-Shelef, M., Lin, K.I., McHeyzer-Williams, L.J., Liao, J., McHeyzer-Williams, M.G., and Calame, K. (2003). Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity *19*, 607–620.

Shou, Y., Martelli, M.L., Gabrea, A., Qi, Y., Brents, L.A., Roschke, A., Dewald, G., Kirsch, I.R., Bergsagel, P.L., and Kuehl, W.M. (2000). Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc. Natl. Acad. Sci. USA *97*, 228–233.

Spitz, F., and Furlong, E.E. (2012). Transcription factors: from enhancer binding to developmental control. Nat. Rev. Genet. *13*, 613–626.

Taatjes, D.J. (2010). The human Mediator complex: a versatile, genome-wide regulator of transcription. Trends Biochem. Sci. *35*, 315–322.

Thanos, D., and Maniatis, T. (1995). Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 83, 1091–1100.

Turner, C.A., Jr., Mack, D.H., and Davis, M.M. (1994). Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell *77*, 297–306.

Weinstein, I.B. (2002). Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297, 63-64.

Whyte, W.A., Orlando, D.A., Hnisz, D., Abraham, B.J., Lin, C.Y., Kagey, M.H., Rahl, P.B., Lee, T.I., and Young, R.A. (2013). Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, this issue, 307-319.

Wu, S.Y., and Chiang, C.M. (2007). The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J. Biol. Chem. *282*, 13141– 13145.

Wu, S.Y., Zhou, T., and Chiang, C.M. (2003). Human mediator enhances activator-facilitated recruitment of RNA polymerase II and promoter recognition by TATA-binding protein (TBP) independently of TBP-associated factors. Mol. Cell. Biol. *23*, 6229–6242.

Wu, S.Y., Lee, A.Y., Lai, H.T., Zhang, H., and Chiang, C.M. (2013). Phospho switch triggers brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol. Cell *49*, 843–857.

Yang, Z., Yik, J.H., Chen, R., He, N., Jang, M.K., Ozato, K., and Zhou, Q. (2005). Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell *19*, 535–545.

You, J.S., and Jones, P.A. (2012). Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22, 9–20.

Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li, W., and Liu, X.S. (2008). Modelbased analysis of ChIP-Seq (MACS). Genome Biol. *9*, R137.

Zhang, W., Prakash, C., Sum, C., Gong, Y., Li, Y., Kwok, J.J., Thiessen, N., Pettersson, S., Jones, S.J., Knapp, S., et al. (2012). Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J. Biol. Chem. 287, 43137–43155.

Zuber, J., Shi, J., Wang, E., Rappaport, A.R., Herrmann, H., Sison, E.A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011). RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524–528. AR, we investigated the copurification of phosphorylated forms of EZH2 and AR by gel filtration and found that pS21 EZH2 predominantly coeluted with AR in a high–molecular weight complex (Fig. 4D). These results suggest a potential role for EZH2 phosphorylation at Ser²¹ to promote its association with an AR-containing complex.

The importance of EZH2 phosphorylation at Ser²¹ in prostate cancer progression was further analyzed by immunohistochemistry in tissue microarrays containing early-stage prostate tumors from a neoadjuvant androgen deprivation therapy trial and metastatic, hormone-refractory tumors (Fig. 4E and fig. S19). As previously reported (1), the level of EZH2 in CRPC was higher than during early-stage disease, and pS21 EZH2 was even more significantly increased in CRPC. Intriguingly, H3K27me3 levels significantly decreased with prostate cancer progression, consistent with our observation that the global level of H3K27me3 in abl cells was considerably lower than in LNCaP cells (Fig. 1A). This result further supports our conclusion that the oncogenic activity of EZH2 in CRPC is independent of its Polycomb-repressive function.

This study demonstrates that phosphorylation of EZH2 at Ser²¹, mediated directly or indirectly by the PI3K-Akt pathway, can switch its function from a Polycomb repressor to a transcriptional coactivator of AR (and potentially other factors). Rescue experiments and the lack of correlation with H3K27me3 levels support a role for EZH2-directed methylation of substrates other than H3K27, including potential nonhistone proteins. The current rationale for EZH2 inhibitor design is based primarily on targeting its Polycomb-repressive activity and uses H3K27me3 as the pharmacodynamic readout (19). However, the observed loss-of-function mutations of EZH2 in myelodysplastic syndrome and acute leukemia raise concerns that such inhibitors might exhibit important hematologic side effects (20, 21). Our finding of an altered function for EZH2 in CRPC cells raises the potential to develop inhibitors that specifically target the EZH2 activation function while sparing its PRC2-repressive function. In addition, our finding that EZH2 cooperates with AR-associated complexes and requires phosphorylation to support CRPC growth suggests novel combination therapies for the treatment of metastatic, hormonerefractory prostate cancer (fig. S20).

References and Notes

- 1. S. Varambally et al., Nature 419, 624 (2002).
- 2. R. Cao et al., Science 298, 1039 (2002).
- H. Chen, S. W. Tu, J. T. Hsieh, J. Biol. Chem. 280, 22437 (2005).
- 4. S. T. Lee et al., Mol. Cell 43, 798 (2011).
- D. LaJeunesse, A. Shearn, *Development* 122, 2189 (1996).
- H. Strutt, G. Cavalli, R. Paro, *EMBO J.* 16, 3621 (1997).
- 7. Z. Culig et al., Br. J. Cancer 81, 242 (1999).
- 8. Y. P. Yu et al., J. Clin. Oncol. 22, 2790 (2004).
- 9. S. Varambally et al., Cancer Cell 8, 393 (2005).
- G. V. Glinsky, A. B. Glinskii, A. J. Stephenson, R. M. Hoffman, W. L. Gerald, *J. Clin. Invest.* **113**, 913 (2004).
- 11. R. Cao, Y. Zhang, Curr. Opin. Genet. Dev. 14, 155 (2004).

- A. Kuzmichev, K. Nishioka, H. Erdjument-Bromage, P. Tempst, D. Reinberg, *Genes Dev.* 16, 2893 (2002).
- 13. P. Joshi et al., J. Biol. Chem. 283, 27757 (2008).
- 14. S. Chen *et al., Nat. Cell Biol.* **12**, 1108 (2010). 15. S. Kaneko *et al., Genes Dev.* **24**, 2615 (2010).
- 16. T. L. Cha *et al.*, *Science* **310**, 306 (2005).
- 17. Y. Wei et al., Nat. Cell Biol. 13, 87 (2011).
- 18. T. Gao, F. Furnari, A. C. Newton, Mol. Cell 18, 13 (2005).
- 19. A. Sparmann, M. van Lohuizen, *Nat. Rev. Cancer* **6**, 846 (2006).
- 20. G. Nikoloski et al., Nat. Genet. 42, 665 (2010).
- 21. P. Ntziachristos et al., Nat. Med. 18, 298 (2012).
- A. Kuzmichev, T. Jenuwein, P. Tempst, D. Reinberg, Mol. Cell 14, 183 (2004).

Acknowledgments: We thank H. Huang, A. Chinnaiyan, Y. Shang, and D. Reinberg for sharing their reagents, and Y. Qiu, X. Yang, J. Xu, and M. Ni for technical support and advice. Supported by a Prostate Cancer Foundation (PCF) Young Investigator Award (K.X.); a Swiss National Science Foundation prospective researcher fellowship (A.C.G.); a NSF graduate research fellowship (J.E.T.); an A. David Mazzone Project Development Award (M.B.); PCF Challenge Awards (S.P.B. and M.B.); U.S. Department of Defense Idea Development Award PC100950 (S.P.B.); National Cancer Institute grants CA131945, CA89021, and CA90381 (M.L.); and NIH grants CA166507 (C.C.), CA111803 (S.P.B.), CA090381 (M.B., S.P.B., P.W.K.), GM99409 (X.S.L.), and CA85859 and CA097186 (C.M., R.L.V.). All data sets have been deposited in the Gene Expression Omnibus database (GSE39461). M.B. serves as a consultant to Novartis Pharmaceuticals.

Supplementary Materials

www.sciencemag.org/cgi/content/full/338/6113/1465/DC1 Materials and Methods Figs. S1 to S20 Tables S1 to S4 References (*23–44*)

17 July 2012; accepted 12 October 2012 10.1126/science.1227604

Airn Transcriptional Overlap, But Not Its IncRNA Products, Induces Imprinted *Igf2r* Silencing

Paulina A. Latos,¹*† Florian M. Pauler,¹*‡ Martha V. Koerner,¹*§ H. Başak Şenergin,¹ Quanah J. Hudson,¹ Roman R. Stocsits,² Wolfgang Allhoff,¹ Stefan H. Stricker,¹ Ruth M. Klement,¹ Katarzyna E. Warczok,¹ Karin Aumayr,² Pawel Pasierbek,³ Denise P. Barlow¹‡

Mammalian imprinted genes often cluster with long noncoding (lnc) RNAs. Three lncRNAs that induce parental-specific silencing show hallmarks indicating that their transcription is more important than their product. To test whether *Airn* transcription or product silences the *Igf2r* gene, we shortened the endogenous lncRNA to different lengths. The results excluded a role for spliced and unspliced *Airn* lncRNA products and for *Airn* nuclear size and location in silencing *Igf2r*. Instead, silencing only required *Airn* transcriptional overlap of the *Igf2r* promoter, which interferes with RNA polymerase II recruitment in the absence of repressive chromatin. Such a repressor function for lncRNA transcriptional overlap reveals a gene silencing mechanism that may be widespread in the mammalian genome, given the abundance of lncRNA transcripts.

acro long noncoding (lnc) RNAs such as Airn (1), Kcnq1ot1 (2), or Nespas (3) that silence imprinted gene clusters offer important epigenetic models for the numerous lncRNAs mapped in the mammalian genome (4–6). In the Ig/2r imprinted cluster, the paternally expressed Airn (antisense Ig/2r RNA noncoding) macro lncRNA silences in cis the paternal

alleles of *Igf2r*, *Slc22a3*, and *Slc22a2* (1). *Airn* may use different silencing mechanisms, because *Igf2r* is silenced in all embryonic, extraembryonic, and adult tissues that express *Airn*, whereas *Slc22a2* and *Slc22a3* are only silenced in some extraembryonic lineages (7, 8). In support of this, *Slc22a3* silencing in the placenta depends on the *Airn* lncRNA product recruiting EHMT2 histone methyl-

transferase, whereas Igf2r silencing does not (9). Igf2r silencing is also not dependent on Polycombgroup proteins or DNA methylation (10, 11). Thus, the mechanism by which *Airn* silences Igf2r, the only gene in this cluster with an essential embryonic function (12), remains unknown. *Airn* transcription overlaps the Igf2r promoter but not the *Slc22a3* or *Slc22a2* promoters (fig. S1A), indicating that silencing could depend on *Airn* transcriptional overlap independent of the *Airn* lncRNA product.

To test the role of Airn transcription versus product in Ig/2r silencing, we used homologous recombination in embryonic stem (ES) cells to insert polyadenylation (polyA) cassettes on the paternal chromosome that truncate Airn to different Jownloaded from www.sciencemag.org on April 9, 2013

¹CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, 1090 Vienna, Austria. ²Research Institute of Molecular Pathology, Dr. Bohr-Gasse 7, 1030 Vienna, Austria. ³Institute of Molecular Biotechnology, Dr. Bohr-Gasse 3, 1030 Vienna, Austria.

^{*}These authors contributed equally to this work.

[†]Present address: Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK.

[‡]To whom correspondence should be addressed. E-mail: dbarlow@cemm.oeaw.ac.at (D.P.B.); fpauler@cemm.oeaw. ac.at (F.M.P.)

Spresent address: Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh EH9 3]R, UK.

^{||} Present address: UCL Cancer Institute, University College London, London WC1E 6DD, UK.

Fig. 1. Airn is shortened to different lengths by a targeted polyA cassette. (A) Tiling arrays confirm Airn loss upstream of Igf2r in truncated alleles and absence of novel spliced products. Data are relative hybridization intensity plots (13); error bars are means \pm SD of 21 windows of the averaged signal from nine tiled oligos. (B) Loss of Airn 53.2 kb (Airn-mid) and 98.7 kb (Airn-end) upon polyA insertion 3, 16, 31, and 51 kb downstream from the Airn TSS in day 14 differentiated (d14) cells. Airn is not expressed in undifferentiated (d0) ES cells. (C) RNase protection shows normal Airn levels 7.4 kb from the TSS in wild type (WT),



T16, T31, and T51 and its loss in T3. Actin was used as a loading control. y-, probe lacking RNase; y+, probe plus RNase; *T3, MEFs with a previously generated 3-kb truncation (1). (**D**) Reduced spliced + unspliced *Airn* (Airn-

total), but normal levels of unspliced Airn (Airn-uns), upstream of the inserted polyA cassette in four truncated alleles. In (B) and (D), data are means \pm SD of three technical replicates.

lengths (figs. S1 to S5), (13). ES cell differentiation was used to recapitulate the developmental onset of Airn and Igf2r imprinted expression (14) (fig. S1B). PolyA cassettes inserted before (T3, T16) or after (T31, T51) the Igf2r promoter truncated the 118-kb Airn to 3, 16, 31, and 51 kb, respectively (Fig. 1). RNA tiling array hybridization (Fig. 1A) demonstrated Airn truncation and the absence of novel spliced variants in all alleles. Although Airn was lost downstream, normal levels of unspliced Airn were maintained upstream of each truncation site (Fig. 1, B to D, and fig. S3B). Wild-type Airn is mostly unspliced, but 5% of nascent transcripts are spliced to four variants (fig. S1A) that constitute ~30% of steadystate Airn because of their high stability (15). All four truncation alleles showed $\sim 40\%$ loss of total Airn; this reflects a loss of spliced products, as splice acceptors lie downstream of each truncation (Fig. 1D). Together, the truncations of Airn at 3, 16, 31, and 51 kb removed 97.5, 86.5, 73.8, and 56.8% of the 118-kb Airn product, respectively, including all spliced variants. Furthermore, the truncations did not change Airn expression kinetics or its characteristic inefficient splicing, nor did they interfere with the methylation-free state of its paternal promoter (Fig. 1D and fig. S3C).

We next tested whether *Airn* truncation alleles silence the paternal *Igf2r* promoter. *Igf2r* allelic expression was analyzed using two polymerase chain reaction (PCR) assays for steady-state expression. Undifferentiated ES cells showed the expected biallelic *Igf2r* expression in the absence of *Airn* expression (*14*) (Fig. 2A and fig. S6A). Upon differentiation, T3 and T16 cells Fig. 2. The greater part of the Airn lncRNA product is not required for repression of Iqf2r. (A) Allele-specific reverse transcription quantitative PCR (RTqPCR) showing Iqf2r imprinted expression in WT, T31, and T51, but not in T3 or T16, indicated by increased maternal/paternal Iqf2r ratio in differentiated/ d14 ES cells compared to a ratio of ~1 in undifferentiated (d0) cells. Bars show means \pm SD of one to three biological replicates, each with three technical replicates (13). (B) RTqPCR showing total steadystate laf2r in T3, T16, T31, and T51 relative to WT cells; means ± SD as in (A). (C) Igf2r RNA FISH in differentiated (d5) cells shows loss of imprinted Igf2r expression, indicated by increased numbers of cells with double signals in T3 and T16 compared to T51 or WT (fig. S6C shows representative images). Discontinuous transcription of



active genes (*20*) results in many nuclei with no signal using intronic probes. Single spots, imprinted or stochastic biallelic expression; double spots, biallelic expression; *n*, nuclei counted; bars, total counts of two biological replicates and two technical replicates (*13*). (**D**) The paternal *Igf2r* promoter is methylated in differentiated WT, T31, and T51 but not in T3 or T16 cells or in undifferentiated (d0) ES cells, as shown by the 5-kb EcoRI fragment resistant to Notl digestion. *T3, E14 ES cells with a 3-kb *Airn* truncation (*1*); NIH3T3, MEFs with both parental alleles; T^{hp}/+, unipaternal MEFs. T31 cells were assayed on a separate gel.

maintained biallelic Ig/2r expression, whereas T31 and T51 cells showed a gain of Ig/2r imprinted expression similar to wild-type cells. This resulted in a factor of $\sim 2 Ig/2r$ increase in T3 and T16 cells relative to wild-type, T31, and T51 cells

Fig. 3. *Airn* macro lncRNA size and location do not determine *lgf2r* repression. **(A)** The size of the *Airn* RNA FISH signal (white arrow) relative to the nucleus [ring identified by 4',6-diamidino-2-phenylindole (DAPI)] is similar for T51 and T16 but different from WT. Horizontal line denotes median; *P* values are results of *t* tests using two biological replicates performed in two technical replicates (13); *n*, number of nuclei. **(B)** Similar subnuclear localization for WT, T51, and T16 alleles. The nuclear area was binned into pseudo-colored inner, middle, and outer circles with equal spacing, and percentages of *Airn* RNA FISH signals (red arrow) in different distance bins were scored using the same data set as in (A).

(Fig. 2B). The T3 truncation has been examined in a mouse model (1), which validates the ES cell model used here. The data also show that the T3 and T16 truncations do not interfere with Igf2r expression, as the derepressed paternal and



wild-type maternal alleles expressed similar Igf2r levels. Similarly, the T31 truncation cassette inserted on the maternal chromosome allows wildtype Igf2r expression (fig. S3A). Lastly, RNA fluorescence in situ hybridization (FISH) demonstrated loss of Igf2r imprinted expression at a transcriptional level in T3 and T16 but not in T51 cells (Fig. 2C and fig. S6C). Repression of the paternal Igf2r allele is accompanied by gain of DNA methylation on its promoter CpG island (CGI) (14). This methylation is absent in T3 and T16 but is present in T31 and T51 differentiated cells (Fig. 2D and fig. S6B). The T31 allele represses Igf2r and truncates before the first Airn splice acceptor at 37 kb, showing that all spliced Airn variants are unnecessary for Igf2r silencing. The T3 and T16 truncations show that the first 16 kb of Airn are insufficient to silence Igf2r, and the T31 and T51 truncations show that the last 87 kb of Airn are unnecessary. Together, they localize Airn repressor activity to the remaining 12.7% between the T16 and T31 truncations (fig. S6D). Because this region contains the Igf2r promoter, the data support the hypothesis that repressor activity results from Airn transcription.

The nuclear size of the *Aim* lncRNA product correlates with silencing *Slc22a3* in the placenta (9). We used RNA FISH to test whether *Aim* nuclear size or its subnuclear localization correlates with *Igf2r* silencing in embryonic cells. Both parameters showed no difference between



Fig. 4. *Airn* transcriptional overlap is sufficient for *Igf2r* repression. (**A**) Left: Map showing parts of the *Airn* product excluded by T3, T16, T31, and T51 truncation alleles and the region tested by the FAP allele. Right: Wild-type levels of *Airn* are expressed from the FAP but not the RAP allele (means \pm SD of three technical replicates). (**B**) FAP but not RAP cells maintain imprinted *Igf2r* expression. cDNA sequence single-nucleotide polymorphism (SNP) quantitation (fig. S10C) shows increased maternal/paternal ratio in FAP but not RAP cells (means \pm SD of four biological replicates). (**C**) The repressed FAP *Igf2r* promoter has reduced levels of capped mRNA. cDNA sequence SNP quantitation shows the ratio of maternal/paternal capped *Igf2r* mRNA in day 5 differentiated (d5) FAP and RAP cells (mean of two sequence reads per bar; **P* = 0.0001, *t* test). (**D**) Chromatin accessibility in DNase I–treated FAP1 and RAP1 nuclei; blot was hybridized with probe-NE4 to identify the

Igf2r promoter (image levels are nonlinearly adjusted to improve visualization). The repressed FAP *Igf2r* promoter (6-kb FAP-DNase *I*/BgIII fragment) has open chromatin similar to the active RAP promoter (5-kb RAP-DNase *I*/BgIII fragment) (fig. S12A). (**E**) DNA methylation in genomic DNA digested with BgIII and methyl-sensitive NotI, hybridized with probe-NE4. Absence of a 12-kb BgIII fragment in FAP cells indicates an unmethylated (UMe) silent paternal *Igf2r* promoter (fig. S6B). In control R2 Δ /+ cells, the 9.5-kb fragment indicates normal methylation (Me) of the silent paternal *Igf2r* promoter in differentiated ES cells. (**F**) H3K9me3 chromatin immunoprecipitation qPCR on *Airn* and *Igf2r* promoters (P) and *Igf2r* intron1 (B) in FAP (silenced paternal *Igf2r* promoter) and RAP (active paternal *Igf2r* promoter) cells that also contain a silenced maternal *Airn* promoter. Data are means \pm SD of three technical replicates.

REPORTS

T51, which silences Igf2r, and T16, which does not (Fig. 3A and fig. S7). The larger size of wildtype *Airn* is therefore unrelated to Igf2r silencing. The majority of FISH signals lay in the mid-nuclear plane, with both repressing and nonrepressing *Airn* alleles showing a similar localization (Fig. 3B) and a similar relative position to the nucleolus (fig. S7). Together, these data indicate no organizational role for the *Airn* product in Igf2r silencing, thereby supporting claims (9) that *Airn* silences Igf2r and *Slc22a3* by different mechanisms.

A prediction of a transcriptional overlap model is that the interfering promoter should impose repressor activity. To test this, we moved the Airn promoter ~700 base pairs before the Igf2r transcription start site (TSS) in ES cells that lack an endogenous paternal Airn promoter (16) (figs. S8 and S9). FAP (forward Airn promoter) cells contain the repositioned Airn promoter and the first 1.8 kb of the Airn lncRNA product (also present in the T3 and T16 alleles that do not silence Igf2r) in wild-type orientation, and express normal levels of Airn that overlap the paternal Igf2r promoter (Fig. 4A and fig. S9B). RAP (reverse Airn promoter) cells contain an inverted repositioned Airn promoter and do not transcribe Airn over the paternal Igf2r promoter. Undifferentiated ES cells showed biallelic Igf2r expression in FAP or RAP cells (Fig. 4B and fig. S10A) similar to that seen in wild-type cells (Fig. 2A). Upon differentiation, RAP cells maintained biallelic Igf2r expression but FAP cells showed paternal-specific Igf2r silencing with a maternal/paternal Igf2r ratio similar to that in wild-type and T31 and T51 truncated cells. The FAP allele shows that the Airn promoter imposes repressor activity and also excludes the 11-kb Airn region spanning the T16 to FAP insertion sites. Together with the truncation alleles, this excludes 96.7% of the Airn lncRNA product as necessary for silencing Igf2r. The FAP and T31 alleles that both silence Igf2r have in common a 4-kb Airn product that overlaps the Igf2r promoter (Fig. 4A). Another prediction of the transcriptional overlap model is that repressor activity is maintained if the Igf2r promoter is substituted. We previously replaced this 4-kb region in vivo with a Tk-neo reporter gene that preserves imprinted expression and methylation (17). To exclude the possibility that the Tk-neo reporter fortuitously reconstituted endogenous elements, we demonstrated that it lacks any nucleotide or structural similarity to this region (fig. S11). Thus, this 4-kb endogenous Airn product is unnecessary to silence the Igf2r promoter.

These data are consistent with *Airn* silencing the *Igf2r* promoter by transcriptional interference, which reduces recruitment of functional RNA polymerase II (RNAPII) to the *Igf2r* promoter, independent of *Airn* lncRNA products. In FAP cells, the proximity of the repositioned *Airn* promoter prevents a direct analysis of RNAPII on the repressed *Igf2r* promoter. To circumvent this, we assayed for S5P-RNAPII–dependent capped Igf2r mRNA and found that it was reduced in FAP but not in RAP cells (Fig. 4C and fig. S10B). Transcriptional interference models (18) predict suppression of the "sensitive" promoter by an "interfering" promoter, initially in the absence of repressive chromatin. The repressed FAP Igf2r promoter maintained features associated with active chromatin, such as a strong DNase Ihypersensitive site (Fig. 4D and fig. S12, A and B) and H3K4me3 (fig. S12C), similar to the active RAP Igf2r allele. The wild-type paternal Igf2r promoter is modified late in development by DNA methylation that is unnecessary for Igf2r repression in embryo or placenta (10) and by H3K9me3 (15, 19), which is unnecessary for Igf2r silencing in the placenta (9). The repressed FAP Igf2r promoter remained free of DNA methylation (Fig. 4E), possibly due to the proximity of the repositioned Airn promoter CGI. Lowlevel H3K9me3 was less than on the silent Airn promoter by a factor of 10, similar to ratios in mouse embryonic fibroblasts (MEFs) (19), (Fig. 4F). Together, these data show that Airn transcriptional overlap interferes with functional RNAPII recruitment to the Igf2r promoter in the presence of active chromatin, supporting a model whereby Airn induces silencing by transcriptional interference (fig. S12D).

Collectively, our data demonstrate a role for *Airn* transcription, but not its spliced or unspliced lncRNA products, in silencing the *Igf2r* promoter. The demonstration that *Igf2r* silencing depends on *Airn* transcription reflects hallmark features of macro lncRNAs, such as inefficient splicing, extreme length, high repeat content, lack of conservation, and short half-life (*15*), which all indicate that transcription is more important than product. It is not yet known how many of the growing number of mammalian lncRNAs share these hallmarks. If they do, the

range of lncRNA functions in the mammalian genome could be substantially enlarged.

References and Notes

- 1. F. Sleutels, R. Zwart, D. P. Barlow, Nature 415, 810 (2002).
- 2. D. Mancini-DiNardo, S. J. Steele, J. M. Levorse, R. S. Ingram,
- S. M. Tilghman, Genes Dev. 20, 1268 (2006).
 C. M. Williamson et al., PLoS Genet. 7, e1001347
- (2011). 4. M. V. Koerner, F. M. Pauler, R. Huang, D. P. Barlow,
- Development **136**, 1771 (2009).
- 5. S. Djebali et al., Nature 489, 101 (2012).
- M. S. Kowalczyk, D. R. Higgs, T. R. Gingeras, Nature 482, 310 (2012).
- 7. Y. Yamasaki et al., Hum. Mol. Genet. 14, 2511 (2005).
- 8. Q. J. Hudson et al., Dev. Biol. 353, 420 (2011).
- 9. T. Nagano et al., Science 322, 1717 (2008).
- 10. E. Li, C. Beard, R. Jaenisch, Nature 366, 362 (1993).
- J. Mager, N. D. Montgomery, F. P. de Villena, T. Magnuson, *Nat. Genet.* 33, 502 (2003).
- Z. Q. Wang, M. R. Fung, D. P. Barlow, E. F. Wagner, *Nature* 372, 464 (1994).
- 13. See supplementary materials on Science Online.
- 14. P. A. Latos et al., Development 136, 437 (2009).
- 15. C. I. Seidl, S. H. Stricker, D. P. Barlow, *EMBO J.* **25**, 3565 (2006).
- 16. A. Wutz et al., Development **128**, 1881 (2001).
- 17. F. Sleutels, G. Tjon, T. Ludwig, D. P. Barlow, EMBO J. 22,
- 3696 (2003).
 18. A. C. Palmer, J. B. Egan, K. E. Shearwin, *Transcription* 2, 9 (2011).
- 19. K. Regha et al., Mol. Cell 27, 353 (2007).
- 20. C. S. Osborne et al., Nat. Genet. 36, 1065 (2004).

Acknowledgments: We thank E. F. Wagner and A. Wutz for the R2∆ and D3 ES cell lines, and G. Superti-Furga, C. Bock, and A. P. Bird for comments on the manuscript. Array data (GSE41444) are available at www.ncbi.nlm.nih.gov/geo. Supported by grants from Austrian Science Fund FWF (F4302-B09 and W1207-B09) and Genome Research in Austria (GEN-AU 820980).

Supplementary Materials

www.sciencemag.org/cgi/content/full/338/6113/1469/DC1 Materials and Methods Figs. S1 to S12 References (*21, 22*)

30 July 2012; accepted 25 October 2012 10.1126/science.1228110

A Steroid Receptor–MicroRNA Switch Regulates Life Span in Response to Signals from the Gonad

Yidong Shen,^{1,2} Joshua Wollam,^{1,2} Daniel Magner,^{1,2} Oezlem Karalay,¹ Adam Antebi^{1,2,3}*

Although the gonad primarily functions in procreation, it also affects animal life span. Here, we show that removal of the *Caenorhabditis elegans* germ line triggers a switch in the regulatory state of the organism to promote longevity, co-opting components involved in larval developmental timing circuits. These components include the DAF-12 steroid receptor, which is involved in the larval stage two—to—stage three (L2-L3) transition and up-regulates members of the *let-7* microRNA (miRNA) family. The miRNAs target an early larval nuclear factor *lin-14* and *akt-1/*kinase, thereby stimulating DAF-16/FOXO signaling to extend life. Our studies suggest that metazoan life span is coupled to the gonad through elements of a developmental timer.

S tudies of the nematode *Caenorhabditis* elegans have shown that these animals live up to 60% longer when germline stem cells (GSCs) are eliminated from the gonad (1, 2). This longevity depends on the presence of the somatic gonad, suggesting a model wherein